Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 6/20 | 0.42 |
| ▸ | PPARD | Q03181 | 6/20 | 0.42 |
| ▸ | PPARA | Q07869 | 6/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | FABP4 | P15090 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3361168 | 0.85 | LMNA (0.48) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL3545824 | 0.84 | — | — | |
| SCHEMBL6355102 | 0.79 | FOLH1 (0.44) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL14359877 | 0.79 | TDP1 (0.54) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL1572851 | 0.79 | LMNA (0.53) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL27567558 | 0.78 | TSHR (0.43) | LMNASLC22A6TSHRNFKB1PMP22 | |
| Hydrochloric Acid SCHEMBL5670619 | 0.77 | LMNA (0.50) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL381203 | 0.77 | LMNA (0.50) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL11662691 | 0.77 | LMNA (0.50) | LMNASLC22A6TSHRNFKB1PMP22 | |
| SCHEMBL6554853 | 0.77 | LMNA (0.50) | LMNASLC22A6TSHRNFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3851126-A1 | MAYTANSINOID-CELL-BINDING AGENT CONJUGATES | ImmunoGen, Inc. (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3524611-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2020-12-30 | — | — | EP | disclosed |
| EP-3524611-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2018-02-15 | — | — | US | disclosed |
| EP-3031810-A1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | ImmunoGen, Inc. (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-1651162-B1 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150071949-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | IMMUNOGEN, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8841425-B2 | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8435528-B2 | Cytotoxic agents comprising new maytansinoids | IMMUNOGEN, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN INC. (US) | 2011-06-30 | — | — | US | disclosed |
| EP-1313738-A4 | PROCESS FOR THE PREPARATION AND PURIFICATION OF THIOL-CONTAINING MAYTANSINOIDS | IMMUNOGEN INC (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004103272-A2 | IMPROVED CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040235840-A1 | For therapy of tumors | IMMUNOGEN, INC. | 2004-11-25 | — | — | US | disclosed |
| EP-1313738-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF THIOL-CONTAINING MAYTANSINOIDS | Immunogen, Inc. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016368-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF THIOL-CONTAINING MAYTANSINOIDS | IMMUNOGEN, INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| US-6333410-B1 | REDUCTIVE HYDROLYSIS OF C3 ESTER WITH LITHIUM TRIMETHOXYALUMINUM HYDRIDE TO YIELD THE MANTANSINOL; ESTERIFYING THE A DISULFIDE-CONTAINING CARBOXYLIC ACID; REDUCING TO YIELD A THIOL-CONTAINING MAYTANSINOID | IMMUNOGEN, INC. | 2001-12-25 | — | — | US | disclosed |
| EP-0425235-B1 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5416064-A | Antitumor agents | IMMUNOGEN, INC. (US) | 1995-05-16 | — | — | US | disclosed |
| US-5208020-A | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC. (US) | 1993-05-04 | — | — | US | disclosed |
| EP-0425235-A2 | Cytotoxic agents comprising maytansinoids and their therapeutic use | IMMUNOGEN INC (US) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235840-A1 | For therapy of tumors | HCCS, SPR, PAICS | LMNA 4857/4885SLC22A6 140/4885TSHR 2061/4885 |
| US-20180043013-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | PDIA4, TPD52L2, ANXA4 | LMNA 4671/4885SLC22A6 107/4885TSHR 1967/4885 |
| US-20110158991-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS | SPR, HCCS, TXNRD1 | LMNA 4677/4885SLC22A6 105/4885TSHR 2549/4885 |
| US-20150071949-A1 | CYTOTOXIC AGENTS COMPRISING NEW MAYTANSINOIDS (DM4) | PDIA4, TPD52L2, ANXA4 | LMNA 4671/4885SLC22A6 107/4885TSHR 1967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.